(i) a 15 to 26-residue deleted peptide or deleted peptide analogue comprising formula (I) which forms an amphipathic α-helix in the presence of lipids and in which one or two helical turns of the peptide or peptide analogue are optionally deleted :

Z_1 -X_1 - X_2 - X_3 - X_4 - X_5 - X_6 - X_7 - X_8 - X_9 - X_{10} - X_{11} - X_{12} - X_{13} - X_{14} - X_{15} - X_{16} - X_{17} - X_{18} - X_{19} - X_{20} - X_{21} - X_{22} -X_{23} -Z_2

or a pharmaceutically acceptable salt thereof, wherein:

X_1 is Pro (P), Ala (A), Gly (G), Gln (Q), Asn (N), Asp (D) or D-Pro (p);

X_2 is an aliphatic residue;

X_3 is a Leu (L) or Phe (F);

X_4 is Glu (E);

X_5 is an aliphatic residue;

X_6 is Leu (L) or Phe (F);

X_7 is Glu (E) or Leu (L);

X_8 is Asn (N) or Gln (Q);

X_9 is Leu (L);

SUB D) Cont

X_{10} is Leu (L), Trp (W) or Gly (G);

X_{11} is an acidic residue;

X_{12} is Arg (R);

X_{13} is Leu (L) or Gly (G);

X_{14} is Leu (L), Phe (F) or Gly (G);

X_{15} is Asp (D);

X_{16} is Ala (A);

X_{17} is Leu (L);

X_{18} is Asn (N) or Gln (Q);

X_{19} is a basic residue;

X_{20} is a basic residue;

X_{21} is Leu (L);

X_{22} is a basic residue;

X_{23} is absent or a basic residue;

Z_1 is R_2N- or RC(O)NR-;

Z_2 is -C (O) NRR or -C (O) OR;

each R is independently -H, (C_1-C_6) alkyl, (C_1-C_6) alkenyl, (C_1-C_6) alkynyl, (C_5-C_{20}) aryl, (C_6-C_{26}) alkaryl, 5-20 membered heteroaryl or 6-26 membered alkheteroaryl or a 1 to 7-residue peptide or peptide analogue in which one more bonds between residues 1-7 are independently a substituted amide, an isostere of an amide or an amide mimetic;

SUB D1 Cont

each "-" between residues X_1 to X_{23} and between residues of the peptide to Z_2 independently designates an amide linkage, a substituted amide linkage, an isostere of an amide or an amide mimetic.

56. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 1, in which one helical turn is deleted.

57. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 1, in which three, four, six, seven or eight residues X_1, X_2, X_3, X_4, X_5, X_6, X_7, X_8, X_9, X_{10}, X_{11}, X_{12}, X_{13}, X_{14}, X_{15}, X_{16}, X_{17}, X_{18}, X_{19}, X_{20}, X_{21} and X_{22} are deleted.

58. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 57, in which 3 consecutive residues are deleted.

SUB D2

59. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 57, in which 4 consecutive residues are deleted.

60. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 57, in which two non-contiguous sets of 3 consecutive residues are deleted.

61. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 57, in which two non-contiguous sets of 4 consecutive residues are deleted.

62. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 57, in which one set of 3 consecutive residues and one set of 4 consecutive residues are deleted.

63. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 57, in which 6, 7 or 8 consecutive residues are deleted.

64. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 57, in which residues 19, 20 and 22 are not deleted.

65. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 57, in which residues 3, 6, 9 and 10 are not deleted.

66. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 1, in which X_{23} is absent.

67. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 1 in which:
the "-" between residues designates -C (O) NH- ;
Z_1 is H_2N- ; and
Z_2 is -C (O) OH or a salt thereof.

68. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 1, in which the mean hydrophobic moment, $<\mu_H>$, is about 0.45 to about 0.65.

69. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 68, in which the mean hydrophobic moment, $<\mu_H>$, is about 0.50 to about 0.60.

70. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 1, in which the mean hydrophobicity, $<H_o>$, is about -0.050 to about -0.070.

71. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 1, in which the mean hydrophobicity, $<H_o>$, is about -0.030 to about -0.055.

72. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 1, in which the mean hydrophobicity of the hydrophobic face, $<H_o^{pho}>$, is about 0.90 to about 1.20.

73. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 72, in which the mean hydrophobicity of the hydrophobic face, $<H_o^{pho}>$, is about 0.94 to about 1.10.

SUB D3 cont

74. (Amended) The 15 to 26-residue deleted peptide or deleted peptide analogue of Claim 1, in which the pho angle is about 160° to about 220°.

75. (Amended) The 15 to 26-residue deleted peptide or peptide analogue of Claim 74, in which the pho angle is about 180° to about 200°.

79. (Amended) A pharmaceutical composition comprising an ApoA-I agonist compound and a pharmaceutically acceptable carrier, excipient or diluent, wherein the ApoA-I agonist compound is a deleted peptide or deleted peptide analogue according to Claim 1 or 57.

SUB D4

82. (Amended) The pharmaceutical composition of Claim 79 which is a lyophilized powder.

SUB D5

83. (Amended) The pharmaceutical composition of Claim 79 which is a solution.